09 October 2021: Review Articles
A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy
Qiong Xiang 1ABCEF* , Shuai Dong 1ABDEF* , Xian-Hui Li 2ABCDEFG*DOI: 10.12659/MSM.932772
Med Sci Monit 2021; 27:e932772
Table 1 The development status of PI3Kδ inhibitors.
| Inhibitor | Statement | Description |
|---|---|---|
| Idelalisib (CAL-101) | Launched | CLL, FL, SLL, etc. |
| Duvelisib (IPI-145) | Launched | CLL, FL, SLL, etc. |
| Umbralisib (TGR-1202) | Clinical phase III | CLL, FL |
| ME-401 (PWT-143) | Clinical phase III | FL, CLL |
| Parsaclisib (INCB050465) | Clinical phase II | Myelofibrosis, malignant lymphomas |
| Acalisib (GS-9820) | Clinical phase II | CLL and Lymphoma |
| AMG-319 | Clinical phase II | Inflammation, autoimmune diseases |
| Nemiralisib (GSK2269557) | Clinical phase II | COPD, asthma |
| IC87114 | Launched | PI3K inhibitor in COPD |
| PI-3065 | Launched | Restenosis |
| X-370 | In study | B cell acute lymphoblastic leukemia |